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Abstract
Aberrant and dysregulated protein glycosylation is a
well-established event in the process of oncogenesis
and cancer progression. Years of study on the
glycobiology of cancer have been focused on the
development of clinically viable diagnostic
applications of this knowledge. However, for a
number of reasons, there has been only sparse and
varied success. The causes of this range from
technical to biological issues that arise when studying
protein glycosylation and attempting to apply it to
practical applications. This review focuses on the
pitfalls, advances, and future directions to be taken in
the development of clinically applicable quantitative
assays using glycan moieties from serum-based
proteins as analytes. Topics covered include the
development and progress of applications of lectins,
mass spectrometry, and other technologies towards
this purpose. Slowly but surely, novel applications of
established and development of new technologies
will eventually provide us with the tools to reach the
ultimate goal of quantification of the full scope of
heterogeneity associated with the glycosylation of
biomarker candidate glycoproteins in a clinically
applicable fashion.
Keywords: glycobiomarker, glycopeptide, lectin, lectin
ELISA, mass spectrometry, N-glycosylation, ovarian
cancer, sialic acid.
Protein glycosylation
It is a well-established concept that gene expression and
protein expression are not the sole factors responsible for
phenotype determination. The discovery of the varying
roles of post-translational modifications (PTMs) of
proteins has identified another level at which functional
information is stored. Of the more than 200 different
types of protein PTMs, glycosylation is a frequently
occurring and particularly important one [1-4]. Glycosy-
lation has been shown to have an important role in a
number of physiological processes, including protein
folding and trafficking, cell-cell and cell-matrix interac-
tion, cellular differentiation, fertilization, and the immune
response [5-9]. Approximately half of all mammalian
proteins are glycosylated, with an estimated 3,000 differ-
ent glycan structures recorded (not including all variants
resulting from differences in glycan linkages and anom-
ers), which can vary to a large degree, based on differ-
ences in tissue, cell type, and disease state [10,11]. It is
estimated that 250 to 500 genes are involved in the pro-
tein glycosylation process [12]. Carbohydrate molecules
on proteins can be attached to asparagine residues within
the N-X-S/T consensus sequence when X is not a proline
(N-glycosylation), or to serine or threonine residues
(O-glycosylation). This occurs during or after translation
as the nascent protein is shuttled through the endoplas-
mic reticulum (ER) and subsequent organelles in the
classical secretory pathway (Figure 1). However, glycosy-
lation is not a template-based process such as DNA,
RNA, or protein synthesis, but is rather based on the bal-
ance achieved by the expression and activity levels of the
different glycan attachment and processing enzymes
involved in trimming and addition of monosaccharides,
and on the availability of precursor monosaccharide
molecules, which in turn is dependent on nutrient
resources and expression of other metabolic enzymes
responsible for their synthesis and interconversion
[7,8,13]. This greatly increases the complexity of the pro-
tein glycosylation process, resulting in extensive molecu-
lar microheterogeneity of glycoproteins, and thus the
requirement for a specialized set of tools for their study.
Glycosylation in cancer
Since the initial observation in 1969 showing that mem-
brane glycoproteins of higher molecular weight were
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Figure 1 Life span of glycoproteins from translation to circulation. The translation of signal peptide-containing membrane and secreted
protein occurs on the surface of the endoplasmic reticulum (ER), with the growing peptide chain being shuttled through the translocon
complex into the lumen of the ER. In the ER lumen, core N-glycosylation of accessible N-X-S/T sites is performed by the oligosaccharide
transferase component of the translocon complex while the nascent protein is being translated and folded. Following the completion of
translation, folding, and core glycan processing, the protein is shuttled to the Golgi apparatus, where further N-glycosylation and O-glycosylation
are performed by different glycosyltransferases. In the Golgi, glycoproteins are packaged into secretory vesicles bound for fusion with the plasma
membrane, where the secreted proteins are released into the extracellular space and membrane proteins are presented on the surface of the
cell, making them accessible for cleavage and release by proteolytic enzymes. Once in the extracellular space, these glycoproteins can then enter
the circulation.
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present in transformed mouse fibroblasts compared with
their normal counterparts [14,15], aberrant glycosylation
patterns have been established as a common characteris-
tic of oncologic malignancies. These patterns have been
observed in almost all types of experimental and human
cancers. Even under non-malignant conditions, indivi-
dual glycoproteins are produced in a number of differ-
ent glycoforms [16]. The differences in these forms can
arise from differential occupancy of glycosylation sites
or variability in attached glycan structures. This allows
for great heterogeneity in glycosylation of single proteins
even under normal physiological conditions. However,
under normal physiologic conditions, the distribution of
these glycoforms is stable and reproducible. Once malig-
nant transformation occurs, when underexpression,
overexpression, or neoexpression of glycan moieties can
occur, this balance is disturbed, and can expand the
degree of pre-existing microheterogeneity of individual
proteins [17]. In tumors, the changes in glycan struc-
tures most often arise from disturbances in the expres-
sion and activity levels of different glycosyltransferases
and glycosidases along the secretory pathway, in the ER
and Golgi of cancer cells [18-22]. This can lead to
changes in the structures of both N- and O- linked gly-
cans. For example, increased activity or expression of
N-acetylglucosaminyltransferase V (MGAT5) has been
shown in a number of tumors, resulting in increased
glycan branching on proteins and increased tumor
growth and metastasis [23-27]. Alterations in terminal
glycan residues can also occur during malignancy, which
is often the case with the upregulation of different sialyl-
transferase enzymes in tumors [28-33]. However, it must
be noted that altered glycosylation does not only occur
on proteins produced by the tumor itself, but may
reflect the host’s response to the disease. In patients
with cancer, acute-phase proteins and IgGs have been
shown to have glycosylation patterns distinct from those
found under normal physiological conditions [18].
Therefore, the detection and quantification of the dis-
turbances in protein glycosylation can aid in the screen-
ing and diagnosis of virtually all cancer types.
Glycoprotein cancer biomarkers
Some of the oldest and most common clinically utilized
serological biomarkers for cancer diagnosis and moni-
toring of malignant progression are glycoproteins. Some
of these include prominent glycoprotein biomarkers that
are widely monitored in patients with prostate cancer
(prostate-specific antigen (PSA)), ovarian cancer (carci-
noma antigen (CA)125, mucin 16), colon cancer (carci-
noembryonic antigen (CEA)), and non-seminomatous
testicular carcinoma (human chorionic gonadotropin b-
subunit (hCG-b)) (Table 1). Although all of these pro-
teins have been shown to have aberrant glycosylation
patterns in malignancy [29-37], only their total protein
levels are clinically monitored. Simultaneous measure-
ment of their different glycoforms might increase the
diagnostic potential of these molecules. For two other
common tests, alpha-fetoprotein (AFP) for hepatocellu-
lar carcinoma and CA15-3 (mucin 1 epitope) for breast
cancer, specific glycan structures on these proteins are
monitored, as discussed below.
Some of the most widely used discovery platforms for
the identification of novel glycobiomarkers have been
Table 1 List of common serological tumor markers in clinical use that contain a glycan componenta
Biomarker Type of detection Cancer type(s) Clinical applications References




Diagnosis, staging. detecting recurrence,
monitoring therapy
[153,154]
hCG Protein alone Testicular Diagnosis;staging; detecting recurrence;
monitoring therapy
[154,155]
CA125 Protein alone Ovarian Prognosis; detecting recurrence;
monitoring therapy
[154,156]
CA15-3 Sialylated O-glycan on MUC1 Breast Monitoring therapy [157-159]
CA19-9 SLe on mucin glycoproteins
and gangliosidesa
Pancreatic Monitoring therapy [160,161]
CEA Protein alone Colon Detecting recurrence; monitoring
therapy
[154,157,161]
HER2 Protein alone Breast Therapy selection [157,162,163]
PSA Protein alone Prostate Screening; diagnosis (with digital rectal
examination)
[154,164]
Thyroglobulin Protein alone Thyroid Monitoring [165,166]
CA27-29 MUC1 protein alone Breast Monitoring [161,167]
aModified and adapted from Kulasingam and Diamandis [168]. AFP, alpha-fetoprotein; CA, carcinoma antigen 15-3; CA 19-9, carbohydrate antigen 19-9; CEA,
carcinoembryonic antigen; HER, herceptin; hCG, human chorionic gonadotropin; MRM, multiple reaction monitoring; PSA, prostate-specific antigen; SLe, sialyl
Lewis antigen.
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previously reviewed [17,38-40]. The methods used for
the characterization and analysis of glycan-based cancer
biomarkers currently used clinically and for others in
earlier stages of development have also been previously
reviewed by Adamczyk et al. [41]. In the present review,
we focus on the currently available and potential future
techniques that can be used for the quantification of
glycoprotein biomarkers in biological fluid or serum
patient samples.
There are three general approaches, using a variety of
techniques, by which glycoproteins or carbohydrate epi-
topes can be quantified. The most commonly used
approach involves the measurement of total levels of a
given glycoprotein biomarker. This usually involves the
production of monoclonal antibodies against a given gly-
coprotein, facilitating the development of an assay cap-
able of quantifying total protein levels in the biological
fluid of interest. This is the case with PSA, CA125,
hCG-b, and CEA quantification (Table 1). However, this
type of methodology is not capable of detecting the
changes occurring in the glycosylation patterns of the
target glycoprotein as a result of malignant transforma-
tion, thus missing out on another level of information
that could lead to improved diagnosis and monitoring of
disease. Therefore, even though a glycoprotein is being
measured, its glycan moiety is completely ignored.
Another approach involves the detection and quantifica-
tion of a particular glycan structure shown to be associated
with cancer, such as the antibody-based measurement of
the blood group antigen Lewisa in the CA19-9 assay [42].
This type of approach does not yield any information
about the identity or quantity of the glycoprotein with the
particular carbohydrate epitope, thus also does not include
the full scope of information, which could lead to
improved diagnosis, especially if the protein is produced
directly by the tumor.
The third, most rarely used, and most difficult type of
approach to develop allows for detection and quantification
of both total protein levels and associated glycan structure
(s), such as the measurement of the core-fucosylated spe-
cies of AFP in hepatocellular carcinoma [43,44]. This type
of assay can yield the most information and overcomes
the weaknesses of the other two approaches mentioned
above. Therefore, the development of such a method
would have the most diagnostic benefit.
The potential and the pitfalls
In the past decade or so, there have been significant
advancements in the characterization of the glycosylation
patterns of individual proteins and in the identification of
glycoproteins in a number of complex biological fluids.
This has occurred mostly through the development and
refinement of mass spectrometry techniques and equip-
ment, which, when used in concert with the traditional
methods used for characterization of protein glycosyla-
tion, can provide a powerful complement of tools to
tackle the problem of fully understanding the complexity
and heterogeneity associated with protein glycosylation
and applying the gained knowledge in a clinical setting.
However, there has been limited progress in tapping the
full potential of glycobiomarkers and their dual nature in
order to develop an assay capable of simultaneously deli-
vering information on the absolute quantity of the pro-
tein and of its associated glycan structures in complex
matrices, such as serum, which is the preferred sample
type for high-throughput clinical analysis.
Some of the best and most widely recognized cancer
biomarkers are highly tissue-specific, such as PSA for
prostate tissue, hCG for the placenta, and AFP for the
developing fetus (Figure 2). Using such markers malignant
transformation of cells in a single organ causing the over-
expression or neoexpression of a protein can be detected
and monitored more reliably and earlier in the progression
of the disease, compared with a protein expressed ubiqui-
tously or in multiple tissues. However, proteins with such
characteristics are quite rare. Considering that glycosyla-
tion patterns of the same protein can differ both between
tissues and between normal and transformed cells, the
capability of detecting and quantifying these differences
could confer tissue-/tumor-specific profiles on a large
number of glycoproteins. The ability to perform such a
task reliably, and in a routine fashion, could greatly expand
the field of potential biomarkers and the chances of their
application in the clinical setting.
However, there is a series of technical and biological
obstacles to developing quantitative assays that reflect the
full picture of the status of a glycoprotein biomarker. The
majority of challenges preventing reliable, clinically applic-
able binary measurement of glycoprotein biomarkers are
of a technical nature. More specifically, there is only a very
limited set of tools capable of performing this task, each
with its own set of associated limitations and difficulties.
Currently, the options for concurrent quantification of a
protein and its associated glycans are limited to a combi-
nation of antibody-mediated protein capture and detection
with glycan-specific antibodies, lectins, or mass spectro-
metry. The advancement of these approaches is hindered
by the absence of a suitable recombinant technology cap-
able of reliable and convenient production of glycoproteins
with the desired glycan structures, which would allow for
more convenient and detailed studies. However, because
protein glycosylation is not a template-driven linear
sequence-based process, such as DNA or protein synth-
esis, a suitable solution to this problem does not seem to
be on the horizon, even though some advancements have
been made [45]. Owing to the large number of combina-
tions of branched oligosaccharide structures that can be
created from available monosaccharides in eukaryotic
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cells, and especially cancer cells, where target protein pro-
duction and normal glycosylation processes are greatly dis-
turbed, the staggering glycan microheterogeneity can
significantly impede the precise binary measurement of
individual glycobiomarkers [46]. That is why the majority
of proteins for which the development of these types of
assays has been attempted are high-abundance proteins
themselves (for example, transferrin, haptoglobin, IgGs,
and alpha-1-acid glycoproteins). Therefore, a quantitative
detection system encompassing the heterogeneity of gly-
can structures of a single protein in a single output holds
great potential for bringing the use of more glycobiomar-
kers to a respectable (clinically testable) level.
The majority of the top 22 high-abundance plasma pro-
teins, which account for 99% of protein content in serum,
are glycoproteins [47]. These include such proteins as the
Ig family members, haptoglobin, antitrypsin, and transfer-
rin, among others. However, the majority of potential bio-
markers are found at significantly (several orders of
magnitude) lower levels in the serum. Taking into consid-
eration that a specific glycan profile on one protein might
indicate a malignant condition, but the same profile on
another protein (for example, one of the high-abundance
proteins) might not, the specificity of detection of
low-concentration serum glycoproteins by lectins or even
glycan-specific antibodies can be hindered by high back-
ground levels of contaminating high-abundance glycopro-
teins. Thus, these methods of detection lag far behind the
gold standard (sandwich ELISA) in sensitivity, especially
when taking into account that only a subset of the total
population of the target protein is being measured.
Therefore, in this review, we focus on the technologies
with the capability or a strong potential for binary (pro-
tein and carbohydrate) measurement of glycoprotein
cancer biomarkers in serum, and describe the challenges
associated with the different approaches.
Lectin-based methods
The existence of lectins has been known for over 100
years, since the discovery of ricin by Stillmark in 1888
[48]. However, wider application in research did not occur
until the early 1970s [49,50]. Lectins are proteins with a
proven affinity and selectivity for specific carbohydrate
structures, to which they can bind in a reversible fashion.
Lectins can recognize carbohydrates conjugated to pro-
teins and lipids, or free monosaccharides or polysacchar-
ides. In excess of 500 lectins have been discovered, mostly
of plant origin, and over 100 are commercially available
[48]. They have been used in a wide variety of technical
formats, including lectin blots, immunohistochemistry,
liquid chromatography, and lectin microarrays. Despite
extensive characterization and the many years of experi-
ence with lectin research, there are only a few applications
in which lectins have been used in a clinically applicable
high-throughput fashion to detect and quantify serological























































































































































































































































































































Figure 2 Gene expression of alpha-fetoprotein (AFP), beta-human chorionic gonadotropin (beta HCG), and prostate-specific antigen
(PSA) by tissue. Figure adapted and modified from the BioGPS Application [151], using the HG_U133A/GNF1H Gene Atlas [152].
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reliable tools for glycoprotein characterization, and are
indispensible in any endeavor involving analysis of pro-
tein-associated glycans; however, the lectin journey from
an analytical to a quantitative tool has been a long one,
with many obstacles and few successes.
Enzyme-linked lectin approaches for detection of car-
bohydrates have been known and used for close to 3
decades [51,52]. These types of quantitative assays have
been ported into a high-throughput multiwell plate for-
mat, similar to the common ELISA technique in which
a protein of interest is captured and/or detected by an
antibody, but with lectins taking over the antibody roles.
Over the years, there have been several types of assays,
which can be grouped together under the common
name of ‘enzyme-linked lectin assay (ELLA)’. In one for-
mat, serum or cell-bound proteins are non-specifically
immobilized, and the global levels of a particular glycan
structure are detected using a specific lectin. This has
been performed on the sera of patients with squamous
cell carcinoma of the uterine cervix by measuring the
levels of the Thomsen-Friendenreich antigen (T-Ag)
using the peanut agglutinin (PNA) lectin for detection
[53]. The reactivity of a number of lectins to serum gly-
coproteins from patients with lung cancer was also mea-
sured using this general approach [54]. It has also been
used extensively for detection and differentiation of a
number of species of bacteria [55-57]. In another use of
lectins in an ELLA-type approach, an immobilized lectin
is used to capture all glycoconjugates with a particular
glycan structure from a complex biological sample, and
the presence and quantity of a particular protein is then
determined by antibody detection. An example of this
approach was a study detecting wheat germ agglutinin
(WGA)-bound mucins in the serum of patients with pan-
creatic cancer [58]. However, this approach requires the
target glycoprotein to account for a significantly large
proportion of the total glycoprotein content in the sam-
ple, which is often not the case. Another, more desirable
approach involves the antibody-based capture of a single
protein and subsequent detection of associated glycan
components by lectins. This approach has been used to
measure sialylation of transferrin [59], fucosylation of
PSA in patients with prostate cancer [60], sialylation of
recombinant erythropoietin [61], WGA and ConA reac-
tivity to p185 in the serum of patients with breast cancer
[62], and fucosylation of haptoglobin in the serum of
patients with pancreatic cancer [63].
It must be noted that the antibody-lectin sandwich
approaches are plagued by a number of technical issues,
which can be addressed with varying degrees of success. A
major issue is the inherent glycosylation of the antibodies
used to capture a specific glycoprotein, which can cause a
non-specific background signal from lectin binding, often
masking the signal from the glycoprotein of interest. This
effect can be minimized by the enzymatic or chemical
derivatization of the antibody-associated carbohydrates
prior to use in the assay [59,64,65]. Another issue is the
limited recognition range of any given lectin for a particu-
lar glycan structure, thereby preventing the detection of
the full scope of the heterogeneity of glycosylation on any
particular glycoprotein. Use of multiple lectins for detec-
tion in an array format can ameliorate this issue (see
below). When considering serum as the analyte matrix,
another significant source of background signal in this
type of assay comes from the non-specific contamination
by high-abundance glycoproteins. This often masks the
signal from low-abundance glycoprotein analytes. This is
not an issue when measuring other high-abundance serum
glycoproteins, such as transferrin [59] or haptoglobin [63],
as dilution of the serum sample can lower the background
noise to a minimal level. For low-abundance glycoproteins,
for which sample dilution is not an option, more rigorous
washing and blocking steps are required [66].
The greatest success with use of lectins for the diagnosis
of malignant conditions has been the discovery and quan-
tification of the Lens culinaris agglutinin (LCA)-reactive
species of alpha-fetoprotein (AFP-L3). This has been
shown to improve the specificity for hepatocellular carci-
noma (HCC) compared with total AFP levels, as the latter
can be elevated in pregnancy, hepatitis, and liver cirrhosis
[43,44,67,68]. However, in an ingenious departure from
the ELLA-type approach, in which a lectin replaces an
antibody in an ELISA format, the AFP-L3 test relies on
the liquid-phase capture of AFP reactive to LCA, and sub-
sequent measurement of bound and unbound portions of
the protein by an ELISA for total AFP. Therefore, the
lectin is not used for detection but for fractionation of
the AFP glycoprotein populations in the patient serum,
and the quantification is performed by a standard ELISA
developed with antibodies recognizing peptide (non-glyco-
sylated) epitopes. It is highly fortuitous, given the microhe-
terogeneity associated with AFP glycosylation in HCC,
that only the core fucosylation status of the single N-gly-
cosylation site of AFP, as detected by LCA, is sufficient for
successful diagnosis [69,70].
Over the past decade, a new role has been identified for
lectins in the characterization and quantification of serum
glycoproteins in malignant conditions. In a re-imagination
of the ELLA approach, multiple lectins are now being
used to simultaneously detect different carbohydrate struc-
tures on antibody-captured glycoproteins in a microarray
format. Several groups have created methods in which an
antibody is immobilized in an array format and lectins are
used to measure glycosylation of the captured proteins
[65,71-73]. The major advantage of this approach is the
ability to detect a glycan profile of any given glycoprotein,
and to compare it between different samples in a high-
throughput fashion. Aberrant glycosylation patterns of
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mucins, carcinoembryonic antigen-related cell adhesion
molecule, and alpha-1-beta glycoprotein in clinical sam-
ples from patients with pancreatic cancer have been
detected using similar methods by different groups
[74-76]. This type of approach goes a long way toward
detecting the heterogeneity of glycan structures of indivi-
dual glycoproteins, but at the core, it is only multiplexing
of the ELLA method, with its associated restrictions,
which has been known and applied with limited success
over the past 3 decades.
Mass spectrometry-based methods
Advancements in mass spectrometry (MS) have revolutio-
nized the field of carbohydrate research, and led to the
initiation of a large number of studies dealing with the
identification, analysis, and quantification of glycoconju-
gates [17,77]. With regard to glycosylated proteins, these
studies range from inspections of individual glycoproteins
to elucidation of whole glycoproteomes. Toward these
ends, MS has been coupled to a number of well-estab-
lished, as well as novel technologies, dealing with chemical
modification, chromatographic separation, and affinity
purification of glycans to achieve the best results. These
studies have been conducted on multiple MS platforms,
including ion trap (IT), linear trap quadrupole (LTQ),
time of flight (TOF), quadrupole/triple quadrupole (Q),
Orbitrap, and Fourier transform ion cyclotron resonance
(FTICR) mass analyzers [39]. As a result of its proven uti-
lity, MS analysis has become an almost absolute require-
ment for any study dealing with the identification and
analysis of protein glycosylation. MS-based approaches for
glycoprotein identification, analysis, and characterization
have been reviewed extensively and in a number of publi-
cations [17,39,40,77,78]. Several major groups have
focused on liquid chromatography (LC)-coupled MS
methodologies for glycan analysis, using separation and
enrichment of glycans by hydrophilic interaction liquid
chromatography (HILIC), porous graphitized carbon
(PGC), and reverse-phase (RP) liquid chromatography.
Some examples include studies on HILIC for analysis of
native and derivatized glycans [79-81]; the use of PGC for
enrichment and separation of native glycans [82,83]; and
the work of Alley et al. and Mechref using RP LC [84,85].
However, the quantification of glycoproteins and their
associated glycans using MS techniques is at a nascent
stage, with no clinical applications to date. Similar to the
strategies for identifying and characterizing protein glyco-
sylation, MS can also be used to quantify glycoproteins
only or glycoprotein-associated glycans only, or to simulta-
neously measure both the quantity of the protein and
its associated carbohydrate structure. These quantification
strategies have followed the same trend as the established
MS-based techniques for quantifying proteins. These
can be further separated into label-based or label-free
approaches. Most of the common labeling methods have
involved stable isotopic labeling techniques, such as 16O/
18O, 12C/13C, stable isotope labeling with amino acids in
culture (SILAC), isobaric tags (iTRAQ), and isotope-coded
affinity tags (ICAT) [39]. These strategies are regularly
used for comparison and relative quantification of glyco-
protein analytes between samples. Label-free approaches
have included spectral counting, ion-intensity measure-
ment, and multiple/selected reaction monitoring (MRM/
SRM). However, as can be seen from the majority of the
recent examples in literature shown below, all of these
approaches, and their combinations, have been limited to
quantification of glycoproteins that are highly purified in
background matrices much less complex than serum or
other biological fluids of interest or dealing with one of
the high-abundance proteins.
Although routinely used for identification and character-
ization purposes, an established application of MS in the
glycomics field is the quantification of carbohydrates
released, chemically or enzymatically, from individual or
multiple glycoproteins. MALDI-MS instrumentation has
been shown to be invaluable for this type of approach.
This platform was used by two different groups to quanti-
tate sialylated glycans enzymatically released (PNGase
F-treated) glycoproteins in a high-throughput fashion. For
example, a MALDI-TOF-based methodology was devel-
oped for absolute and relative measurement of up to 34
major N-glycans released from (mostly high-abundance)
serum proteins by optimization of glycan release condi-
tions through development of novel detergent reagents
[86]. The diagnostic and stage stratification potential of
MS-based quantification of permethylated glycans from
serum proteins of patients with breast cancer was shown
by a study that was able to identify and quantify close to
50 different glycan structures [87]. Relative quantification
of anthranilic acid-derivatized glycans enzymatically
released from alpha-1-acid glycoprotein purified from
serum in combination with linear discriminant analysis
has been shown to have the potential to discriminate
between normal individuals and patients with ovarian can-
cer and lymphoma [88]. Similar approaches have also led
to the identification of serum haptoglobin glycans with
diagnostic potential in lung cancer [89] and liver disease
[90].
Quantification of proteins, including some glycopro-
teins, by MRM/SRM and LC-MS has been performed for
a number of biological fluids [91-94]. Great advances
have been made with approaches using immunoaffinity
enrichment of peptides or proteins followed by MRM/
SRM-based quantification, achieving levels of sensitivity
applicable to the concentration range (ng/ml) at which
low-abundance tumor biomarkers are found [95-99].
This type of methodology has also been used in combina-
tion with different types of glycan affinity enrichment
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strategies, thereby producing hybrid assays in which clas-
sic glycoprotein enrichment strategies are used for cap-
ture of specific glycoforms, and MS is used for detection
and quantification of the protein in those subpopulations
by monitoring the MS2 fragmentation of non-glycosy-
lated tryptic peptides. One such example was the quanti-
fication of the phytohemagglutinin-L4 (L-PHA)-enriched
fraction of tissue inhibitor of metalloproteinase 1 from
the serum of patients with colorectal carcinoma and the
supernatant of colon cancer cell lines [100,101]. A num-
ber of high-abundance serum proteins were quantified
recently in the serum of patients with HCC by the same
group using a similar approach of glycoprotein enrich-
ment by lectin and quantification by MRM [102]. Also, a
method for the measurement of total glycosylated and
sialylated PSA has been recently developed, in which per-
iodate-oxidized PSA tryptic glycopeptides are captured
using immobilized hydrazide, released by PNGase F, and
quantified by MRM using a triple quadrupole LC-MS
[103]. However, it must be noted that these types of stu-
dies do not exploit the full potential of MS in detection
of the heterogeneity of glycan structures associated with
any given glycoprotein, but rather use this technology
solely for protein quantification, which could be per-
formed more conveniently and reliably by classic meth-
ods such as ELISA.
The true potential of MS in the quantification of protein
glycosylation lies in the measurement of total levels of the
glycoprotein, while simultaneously measuring its heteroge-
neously glycosylated subpopulations. The ultimate goal is
the development of site-specific label-free methods that
are capable of simultaneously quantifying multiple glyco-
peptides encompassing multiple glycosylation sites and
their different glycoforms, using a non-glycosylated pep-
tide from the glycoprotein of interest or a labeled exogen-
ous peptide standard, which could serve as an indicator of
the total glycoprotein concentration. Considering that
MRM assays have been developed for simultaneous mea-
surement of dozens of tryptic (or other proteolytic) pep-
tides from dozens of proteins, it is not inconceivable that a
similar technique could be developed for glycopeptides
with different glycan structures from a single, or even mul-
tiple proteins. A general schematic of a glycopeptide-
targeted MRM from a single glycoprotein can be seen in
Figure 3A. However, to improve the sensitivity of such
assays, further development and technical advances will be
required.
In addition to the general problems with quantifying
glycoproteins described above, a number of technical
limitations are currently preventing the application of
this type of approach to glycoproteins found in samples
of clinical interest. The major issue is the much lower
ionization efficiency of glycopeptides compared with
their non-glycosylated counterparts, generally following
the trend that ionization efficiency decreases with glycan
branching and sialylation [104,105]. This can result in
differences of several orders of magnitude in absolute
signal values between glycopeptides and non-glycosy-
lated peptides [104,105]. Additionally, compared with
the measurement of non-glycosylated peptides in the
same quantity of the protein analyte, the MRM signal
for any individual glycopeptide (of which there is a het-
erogenous population for any given glycosylation site of
a glycoprotein) will be significantly lower, because it
represents only a subset of a heterogeneous glycoform
population. Major complications can also arise in devel-
oping a glycopeptide quantification method because of
the absence of exogenous glycopeptide standards and
incomplete proteolytic digestion cased by steric hinder-
ence by the glycan chains [104,106,107].
Verification of candidate biomarkers in non-serological
bio-fluids using MRM/SRM assays has become standard
practice in biomarker discovery laboratories. The chal-
lenges associated with the development and optimization
of MRM assays were significantly eased with the advent of
MRM-transition-prediction and data analysis software
such as Pinpoint (Thermo Fisher Scientific Inc., Rockford,
IL, USA) and Skyline (Open-source software, MacCoss
laboratory, University of Washington, Seattle, WA, USA).
Owing to the absence of such invaluable tools for glycan-
bound peptides, MRM development for this use is still a
daunting task. However, the difficulties associated with the
prediction of glycopeptide MRM transitions and their
optimal collision energies can be overcome by monitoring
common oxonium and peptide positive N-acetylhexosa-
mine ions that occur during fragmentation [104,108].
Despite these considerable obstacles, some proof-of-con-
cept studies have been performed. For example, in a recent
study by Song et al., [104] MRM assays were developed for
the quantification of fetuin and alpha1-acid glycoprotein
glycopeptides applicable to serum samples. Kurogochi
et al. have beeen able to develop MRM assays for quantifi-
cation of 25 glycopeptides from 16 glycoproteins found in
serum of mice (Figure 3B) [109]. Specifically, sialic acid
moieties on glycopeptide were oxidized with sodium peri-
odate, enriched for by hydrazide chemistry, labeled with
2-aminopyridine, and the resulting labeled sialoglycopep-
tides were subjected to MS. Preliminary studies have also
been performed with purified RNase B and asialofetuin
[110]. Haptoglobin glycopeptides were characterized
and relatively quantified in serum samples of patients
with psoriasis [111] and patients with pancreatic can-
cer [112]. Ion-current intensities were used to quantify
glycopeptides from alpha-1-acid glycoprotein [113].
The core-fucosylated subpopulations of several glyco-
proteins were quantified using partial deglycosylation
with Endo F3 in conjunction with glycopeptide MRMs
[114]. With the improvement and evolution of MS
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technology and sample-preparation techniques, these
types of assays will play a more prominent role in the
quantification of glycoproteins. In a futuristic scenario,
to construct high-throughput platforms for the verifi-
cation of cancer-exclusive glycoforms, these MRM-MS
assays could be coupled to robotic immunoaffinity
enrichment methods [115].
Alternative strategies
Although lectin and MS-based approaches for quantifica-
tion of glycoproteins are the most common, there are
other technologies that are also applied, and new ones
are being developed, to be used alone, or in combination
with each other. Well-established liquid-chromatography
techniques using HILIC or PGC are readily available for
enrichment and separation of glycan and glycoconjugates
in conjunction with other detection and quantification
methods [116-118]. The most established affinity-binding
agents for quantification of proteins and other molecules
are antibodies, and the ELISA still remains the gold stan-
dard for the clinical measurement of serological targets.
However, glycan-specific antibodies are extremely rare
compared with antibodies recognizing peptide epitopes,
and their use in the field is limited compared with lectins.
This is because carbohydrates have been shown to be
poor immunogens, and their antibodies have affinities
comparable with those of lectins, but with a much more
difficult development process. In addition, antibodies
Mass filter 1: Mass filter 2: 





Figure 3 Glycopeptide MRM/SRM. (A) General schematic representation of multiple reaction monitoring (MRM). Peptides and glycopeptides
from a protease (normally trypsin)-cleaved glycoprotein are subjected to triple quadrupole mass spectrometry (MS). Only selected parent ion
ions were selected for fragmentation, and the resulting fragment ion intensities were used for (glyco)peptide quantification. (B) Representative
chromatogram of simultaneous MRMs of 25 pyridyl amineated sialoglycopeptides found on 16 glycoproteins in mouse serum. Adapted and
modified from Kurogochi et al. [109].
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detecting an epitope that encompasses a part of a given
protein’s sequence, while at the same time recognizing its
glycan structure, thereby giving site and glycoprotein spe-
cificity, are extremely rare. Therefore, the possible advan-
tage of using a glycan-specific antibody over a
comparable lectin is minor. The issue of cross-reactivity
has been brought up for Tn antigen-recognizing antibo-
dies [119]. In a recent study, 27 commonly used carbohy-
drate-binding antibodies against histo-blood group,
Lewis, and tumor antigens were examined for their speci-
ficity using a glycan/glycoprotein array [120]. Although
some showed high specificity and affinity for their targets,
almost half of them exhibited cross-reactivity for other
glycan structures. In cancer research, the role of such
antibodies has been mostly limited to indirect quantifica-
tion by immunohistochemistry and blotting. When con-
sidering applications of glycan-specific antibodies for
serological markers of malignancy, the CA 19-9 and CA
15-3 tests stand out. By using a sandwich ELISA, the CA
19-9 test measures the serum levels of sialyl Lewisa anti-
gen on glycoproteins and glycolipids, and is used for
monitoring of pancreatic cancer progression and recur-
rence, and for differentiation of the cancer from pancrea-
titis [42,121,122]. The CA 15-3 test is used to quantify a
sialylated O-glycosylation epitope on mucin 1 (MUC1),
and is used for prognosis and monitoring of treatment
for breast cancer [123,124].
Chromatography-based strategies have also been used
with some success. Ion-exchange chromatography is
being used clinically for separation and quantification of
serum transferrin glycoforms to test for congenital dis-
orders of glycosylation [125,126]. KLK6 glycoforms have
also been measured in a number of biological fluids,
including serum, from patients with ovarian cancer at
low concentrations (down to 1 ng/ml) using strong
anion exchange for separation and ELISA for quantifica-
tion [127]. Novel strategies are also being used for the
development of new carbohydrate-recognizing agents,
which could be used in a quantitative fashion. Phage
display technology has been used to improve and alter
the binding properties of glycan-binding modules of gly-
can-processing enzymes and for development of carbo-
hydrate-binding peptides [128-132]. The technique of
systematic evolution of ligands by exponential enrich-
ment (SELEX) has been applied to the development of
aptamers, single-stranded DNA or RNA oligonucleo-
tides, which have been tried as binding agents for a
number of carbohydrate moieties [130,133-137]. The
more recent advancements and nascent technologies
developed for carbohydrate detection, also referred to as
glyco-biosensors, have been reviewed extensively
[1,138,139]. Some of these include electrochemical
impedance spectroscopy [140-143], molecular ‘tweezers’
[144], nanoparticle displacement methods [145], quartz
crystal microbalance [146,147], and surface plasmon
resonance [148-150]. However, these technologies are
garnered towards highly controlled in vitro systems, and
will require further testing before application in a clini-
cal setting.
Conclusions and perspectives
The clinical potential of glycoprotein biomarkers in can-
cer is indisputable. Some valuable successes have been
achieved in the field, yet there is much room for
improvement. The majority of the tools currently avail-
able have proven their utility beyond doubt when used
for qualitative and characterization purposes. However,
for each of these technologies, the leap from analytical
to quantitative applications has not been sufficiently
successful.
Over the next decade, the major goal will be the reli-
able detection and quantification of the full scope of gly-
can heterogeneity on any particular glycoprotein of
interest, and the ability to differentiate these patterns
between homeostatic and disease conditions. When the
recent literature is searched for ‘glycosylation quantifica-
tion’, it quickly becomes obvious that MS-based
approaches have almost become an absolute require-
ment. However, when viewing the field as a whole, one
gets an appreciation of the fact that MS advancements
alone will not bring a major breakthrough. In the near
future, the development of even more new glycan-recog-
nition agents can be expected, such as novel naturally
occurring or recombinant lectins, carbohydrate-recog-
nizing antibodies, aptamers, and other glycobiosensors.
Progress is also being made in the engineering and syn-
thetic production of protein glycosylation, which will
greatly aid in the creation of standards and uniform
model systems for development of precise quantitative
assays. In the near future, the predominance and expan-
sion of immuno-based and lectin-based methods in
practical applications of glycan quantification can be
expected, especially given the recent advances in micro-
array technology. We believe that MS holds the greatest
potential, but it is still hampered by a number of techni-
cal limitations, which will require significant technologi-
cal progress to be made before it will be sufficiently
reliable and applicable in the most appropriate manner.
Nonetheless, we believe that MS is the most promising
tool for detection and quantification of the full scope of
protein-associated glycosylation down to the single
monosaccharide unit level. The future appears bright,
and progress in the field is inevitable; the only uncer-
tainty is how long it will take.
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